CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and orphan diseases, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Tuesday, August 12, 2014 to report its second quarter 2014 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-800-901-5241 (domestic) or 1-617-786-2963 (international) and provide the access code 28510971. The live webcast can be accessed under “Investor Events” in the Investors section of the Company’s website at www.iderapharma.com.
A replay of the call will be available at 1:30 p.m. EDT on August 12, 2014 until 11:59 p.m. EDT on August 19, 2014. To access the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and reference the access code 67213242. The archived webcast will be available for 90 days in the Investors section of Idera’s website at www.iderapharma.com.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA